The pharmaceutical industry is one of the most regulated and quality-sensitive sectors in the world.
The quality and safety of medicines depend not only on how they are manufactured, but also on how they are distributed throughout the supply chain and this is where Good Distribution Practice comes into play.
From the manufacturer to the wholesaler, from the wholesaler to the retailer, and from the retailer to the patient, every step of the distribution process must ensure that the medicines are handled, stored, and transported under suitable conditions, as required by the marketing authorisation or product specification.
Good distribution practices (GDP) are a set of standards that aim to ensure the quality and integrity of medicines during the distribution process. GDP covers the sourcing, handling, storage, and transportation of medicines for human use and their active ingredients. Compliance with GDP helps to prevent contamination, deterioration, adulteration, theft, and diversion of medicines. It also helps to ensure the traceability and recall of medicines in case of quality defects or safety issues.
GDP is part of the quality assurance system that applies to the pharmaceutical industry. It is based on the principles of good manufacturing practice (GMP), which is the minimum standard that a medicines manufacturer must meet in their production processes. GMP and GDP are both regulated by the national competent authorities and the European Medicines Agency (EMA) in the European Union (EU), and by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK). They are also guided by the directives and guidelines issued by the European Commission and the World Health Organization (WHO).
GDP applies to all organisations that are involved in the distribution of medicines, such as manufacturer licence holders, wholesale dealer licence holders, blood establishment authorisation holders, and non-UK sites employed by UK marketing authorisation holders, and transportation companies contracted to collect and deliver the medicinal products.
These organisations are required to obtain a licence or authorisation from the relevant authority and to undergo periodic inspections to check their compliance with GDP. The inspections are based on a risk assessment and may be announced or unannounced. The inspectors will evaluate the organisation's quality system, personnel, premises, equipment, documentation, operations, complaints, recalls, and self-inspections.
The benefits of complying with GDP are manifold. For the organisations, it can help to improve their reputation, customer satisfaction, and business performance. It can also help to reduce the risks of legal liability, regulatory sanctions, and financial losses. For the patients, it can help to ensure that they receive medicines that are of consistent high quality, appropriate to their intended use, and meet the requirements of the marketing authorisation or product specification.
GDP is not a static concept, but a dynamic and evolving one. It needs to adapt to the changing needs and challenges of the pharmaceutical industry, such as the emergence of new technologies, the increase of globalisation, the diversification of supply chains, and the rise of counterfeit and falsified medicines. Therefore, it is important for the organisations to keep abreast of the latest developments and updates on GDP and to implement them in their daily operations.
GDP is a key element of the quality assurance system that ensures the quality and safety of medicines throughout the distribution process. By complying with GDP, the organisations can demonstrate their commitment to delivering high-quality medicines to the patients and to protecting public health.
It is recommended to have an approved and registered consultancy train your staff in Good Distribution Practice.
If you need help, we can offer a free over-the-phone initial consultation on 0330 133 0920 or you can email us on info@ukgdpassociation.co.uk. Alternatively, use the contact form at the top right of this screen.
You can also view more posts with useful data and information on this blog page. Below is a selection:
Self Inspections & First Party Audits
Why Management Reviews are Important
WHAT IS A QMS (Quality Management System)?
Continue reading with these related articles from the GDP community.
Guidance
In today’s pharmaceutical landscape, GDP compliance is no longer a back-office responsibility - it’s a make-or-break factor that can elevate or collapse your distribution credibility. UK wholesalers, distributors, and pharmaceutical outlets are...
Guidance
The pharmaceutical industry, while dedicated to healing and well-being, has a significant environmental footprint. From manufacturing to distribution, the processes involved consume considerable energy and resources. As sustainability becomes an...
As the pharmaceutical distribution landscape continues to evolve, ensuring compliance with Good Distribution Practice (GDP) remains paramount for UK wholesalers. With increasing regulatory scrutiny and the complexities of modern supply chains,...